AAA April 2016 – Page 5

Alcon turns on series D funding for PowerVision

US-based eyecare technology developer PowerVision has extended its series D round to $40m, according to a regulatory filing on Tuesday, having secured funding from Alcon, an eyecare subsidiary of pharmaceutical firm Novartis. Founded in 2002, PowerVision is developing an intraocular implant for patients suffering from cataracts and presbyopia, a type of farsightedness associated with old… Continue reading Alcon turns on series D funding for PowerVision

Second Genome raises $42.6m in third funding round

US-based biopharmaceutical company Second Genome raised $42.6m yesterday in a series B round co-led by pharmaceutical firms Pfizer and Roche, which invested through their respective Pfizer Venture Investments and Roche Venture Fund units. Medical research organisation Mayo Clinic also took part in the round, as did Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, Advanced… Continue reading Second Genome raises $42.6m in third funding round